Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence ADSGEGDFLAEGGGVR
Primary information
sequence IDSeq_199
Peptide sequenceADSGEGDFLAEGGGVR
CancerPDF_ID CancerPDF_ID9, CancerPDF_ID187, CancerPDF_ID192, CancerPDF_ID225, CancerPDF_ID633, CancerPDF_ID1027, CancerPDF_ID1218, CancerPDF_ID2323, CancerPDF_ID3450, CancerPDF_ID3594, CancerPDF_ID4118, CancerPDF_ID8501, CancerPDF_ID9676, CancerPDF_ID10181,
PMID16896061,19728888,19728888,19728888,19795908,16395409,21136997,21136997,27026199,27026199,24982608,23667664,21533267,21805675
Protein NameFibrinogen alpha chain,fibrinopeptide A;,phospho-fibrinopeptide A,Phospho-fibrinopetide A,Fibrinogen alpha chain,Fibrinopeptide A,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,Isoform 1 of Fibrinogen alpha chain,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain
UniprotKB Entry NameFIBA_HUMAN,NA,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN
FluidSerum,Serum,Serum,Serum,Plasma,Serum,Serum,Plasma,Urine,Urine,Urine,Serum,Serum,Urine
M/Z1536.68,1536.6906,1616.6366,1616.6366,768.85,1536.68,1535.68521,1535.6852,NA,NA,NA,1535.69,768.83,1536.7024
Charge1,NA,NA,NA,2,1,1,1,NA,NA,NA,1,2,NA
Mass (in Da)1536.69,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1537.58,NA,NA
fdrNA,NA,NA,NA,NA,NA,NA,NA,1535.69,1535.69,NA,NA,NA,NA
Profiling TechniqueMALDI-TOF,MALDI-TOF,MALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,"CE-MS, Micro-TOF-MS","CE-MS, Micro-TOF-MS",Nano-LC-MS,MALDI-TOF,LC-MS,MALDI-TOF
Peptide Identification techniqueQ/TOF MS/MS,LC-MS/MS,LC-MS/MS,LC-MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,MS-MS,MS-MS,MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,MALDI-TOF-MS
Quantification TechniqueNA,NA,NA,NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,NA,NA,NA,NA,Multiple Reaction Monitoring,NA
Labelled/Label FreeLabel Free,Label Free,Label Free,Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free
FDRNA,NA,NA,NA,less than 7%,less than 1 “5,NA,0.001,NA,NA,0.01,NA,1.49,1
CancerPDF_ID CancerPDF_ID9, CancerPDF_ID187, CancerPDF_ID192, CancerPDF_ID225, CancerPDF_ID633, CancerPDF_ID1027, CancerPDF_ID1218, CancerPDF_ID2323, CancerPDF_ID3450, CancerPDF_ID3594, CancerPDF_ID4118, CancerPDF_ID8501, CancerPDF_ID9676, CancerPDF_ID10181,
p-Value1.00E-05,less than 0.01,less than 0.05,less than 0.01,NA,5.10E-12,NA,3.30E-07,less than 0.05,less than 0.001,NA,NA,6.41E-23,NA
SoftwareMASCOT,MASCOT(v 2.0.04 for Windows),MASCOT(v 2.0.04 for Windows),MASCOT(v 2.0.04 for Windows),FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),Proteome Discoverer 1.2,Proteome Discoverer 1.2,"GPM search engine, MASCOT",MASCOT,MASCOT,NA
Length16,16,16,16,16,16,16,16,16,16,16,16,16,16
Cancer TypeMetastatic thyroid carcinomas,"Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy","Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy","Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy",Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,Bladder cancer,Bladder cancer,Ovarian cancer,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Muscle-invasive bladder cancer
DatabaseNCBI refseq Protein Database,SwissProt Database (release 54.7),SwissProt Database (release 54.7),SwissProt Database (release 54.7),NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,Uniprot Human non-redundant Database,Uniprot Human non-redundant Database,IPI 3.71 Human Database ,NA,Swissprot Database (57.4),SwissProt Database
ModificationNA,NA,Ser at 3rd is phosphorylated,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"11 NSCLC patients with the shortest PFS, 11 patients with the longest PFS","11 NSCLC patients with the shortest PFS, 11 patients with the longest PFS","27 patients, 13 normal individuals","42 normal, 28patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,27 healthy individuals,451 for training (341 patients and 110 normal) and 270 for testing(168 primary UBC patients and 102 normal controls);, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls),6 Ovarian cancer patients and 6 normal individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,751 bladde
RegulationNA,Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS,Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS and Peptide signature for differentiation between healthy and NSCLC patients,Differentially expressed between NSCLC patients vs healthy volunteers,NA,"Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.58, 0 and 0.54 in prostate, bladder and breast cancer respectively",NA,Differentially expressed between cancer vs normal,Differentially expressed between primary UBC and normal individual,Differentially expressed between recurrence of UBC vs recurrence control,Uniquely present in case of urine of ovarian cancer patients,NA,Differentially expressed between Lung cancer vs control,Differentially expressed between cancer vs normal samples
ValidationIndependent validation,Independent validation,Independent validation,Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,Independent Validation,Independent Validation,NA,NA,MRM-based validation of 19 candidates,Mann-Whitney tests and areas under receiver-operator characteristic
Sensitivity95% on independent dataset,1,1,1,NA,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA,0.898,For testing dataset 91%,For testing dataset 88%,NA,NA,NA,NA
Specificity95% on independent dataset,0.73,0.73,0.96,NA,NA,NA,0.946,For testing dataset 68%,For testing dataset 51%,NA,NA,NA,NA
AccuracyNA,0.86,0.86,0.98,NA,97.5 % on validation dataset,NA,0.917,For testing dataset 76%,NA,NA,NA,0.804,NA
Peptide AtlasPeptideAtlas
IEDB